Want to join the conversation?
Pharmaceutical company $AGN said that VIBERZI (eluxadoline), a twice daily, oral medication that is used for first-in-class treatment for irritable bowel syndrome with diarrhea (IBS-D) in adults, is now available by prescription in the US. This medication relieves the core symptoms of IBS-D, diarrhea and abdominal pain.
$YHOO is reporting today after market close. Nobody cares about this stock.
$WBA is yet to receive US anti-trust clearance for its Rite Aid acquisition. The deadline for the deal expires on January 27.
$BMY plunge 7.2%. No credits to the non-acceleration of approval for lung cancer combination treatment.